DK0776895T3 - Proteinkinase C inhibitor - Google Patents

Proteinkinase C inhibitor

Info

Publication number: DK0776895T3
Authority: DK; Denmark
Prior art keywords: inhibitor; protein kinase; kinase; protein
Prior art date: 1995-11-20

Application number

DK96308318T

Other languages

Danish (da)

English (en)

Inventor

Michael Robert Jirousek

Margaret Mary Faul

Gary Lowell Engel

Nagy Alphonse Farid

Lori Ann Richardson

Leonard Larry Winneroski Jr

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-20

Filing date

1996-11-18

Publication date

1999-06-23

1996-11-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-06-23 Application granted granted Critical

1999-06-23 Publication of DK0776895T3 publication Critical patent/DK0776895T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK96308318T 1995-11-20 1996-11-18 Proteinkinase C inhibitor DK0776895T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US697095P	1995-11-20	1995-11-20

Publications (1)

Publication Number	Publication Date
DK0776895T3 true DK0776895T3 (da)	1999-06-23

Family

ID=21723527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96308318T DK0776895T3 (da)	1995-11-20	1996-11-18	Proteinkinase C inhibitor

Country Status (34)

Country	Link
US (3)	US5710145A (cs)
EP (1)	EP0776895B1 (cs)
JP (1)	JP3348859B2 (cs)
KR (1)	KR100304210B1 (cs)
CN (1)	CN1093759C (cs)
AR (2)	AR004717A1 (cs)
AT (1)	ATE172199T1 (cs)
AU (1)	AU711125B2 (cs)
BR (1)	BR9611724A (cs)
CA (1)	CA2237221C (cs)
CO (1)	CO4750823A1 (cs)
CY (1)	CY2103B1 (cs)
CZ (1)	CZ297524B6 (cs)
DE (1)	DE69600784T2 (cs)
DK (1)	DK0776895T3 (cs)
EA (1)	EA000967B1 (cs)
EG (1)	EG23871A (cs)
ES (1)	ES2122764T3 (cs)
HU (1)	HU226821B1 (cs)
IL (1)	IL124417A (cs)
MX (1)	MX9803792A (cs)
MY (1)	MY118068A (cs)
NO (1)	NO310196B1 (cs)
NZ (1)	NZ323571A (cs)
PE (1)	PE22798A1 (cs)
PL (1)	PL184715B1 (cs)
RO (1)	RO120074B1 (cs)
SI (1)	SI0776895T1 (cs)
TR (1)	TR199800759T2 (cs)
TW (1)	TW403754B (cs)
UA (1)	UA61897C2 (cs)
WO (1)	WO1997018809A1 (cs)
YU (1)	YU49315B (cs)
ZA (1)	ZA969646B (cs)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
AR017200A1 (es)	1997-12-23	2001-08-22	Astrazeneca Ab	Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
KR100610127B1 (ko) *	1998-01-30	2006-08-09	다이소 가부시키가이샤	부탄트리올 유도체의 제조 방법
US6291446B1 (en)	1998-03-05	2001-09-18	Eli Lilly And Company	Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en)	1998-03-05	2001-05-01	Eli Lilly And Company	Therapeutic treatment for renal dysfunction
US6103713A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for autoimmune diseases
US6103712A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for asthma
SE9800835D0 (sv)	1998-03-13	1998-03-13	Astra Ab	New Compounds
CA2245029A1 (en)	1998-03-13	1999-09-13	University Of British Columbia	Granulatimide compounds as g2 checkpoint inhibitors
WO1999047522A1 (en) *	1998-03-13	1999-09-23	The University Of British Columbia	Granulatimide derivatives for use in cancer treatment
US6706721B1 (en) *	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en)	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
TWI223598B (en) *	1998-06-22	2004-11-11	Pfizer Ireland Pharmaceuticals	An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
US6841567B1 (en) *	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en)	1999-05-21	2002-12-10	Astrazeneca Ab	Pharmaceutically active compounds
US6284783B1 (en)	1999-06-09	2001-09-04	The Uab Research Foundation	Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en)	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
US7087613B2 (en) *	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6852688B2 (en)	2000-03-10	2005-02-08	University Of Florida	Compositions for treating diabetic retinopathy and methods of using same
US20030224415A1 (en) *	2001-06-29	2003-12-04	Gala Design, Inc.	Selection free growth of host cells containing multiple integrating vectors
US6852510B2 (en)	2000-07-03	2005-02-08	Gala Design Inc	Host cells containing multiple integrating vectors
WO2002002783A2 (en) *	2000-07-03	2002-01-10	Gala Design, Inc.	Expression vectors
US6300106B1 (en) *	2000-11-22	2001-10-09	Ppg Industries Ohio, Inc.	Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US7384738B2 (en) *	2002-03-28	2008-06-10	Bremel Robert D	Retrovirus-based genomic screening
US20040038304A1 (en) *	2002-03-28	2004-02-26	Gala Design, Inc.	Antibody libraries
AU2003241398A1 (en) *	2002-05-06	2003-11-17	Washington University	Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
DE10244453A1 (de) *	2002-09-24	2004-04-01	Phenomiques Gmbh	Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) *	2003-01-10	2007-06-19	Board Of Trustees Of The Leland Stanford Junior University	Kinase inhibitors and associated pharmaceutical compositions and methods of use
ATE457995T1 (de)	2003-06-18	2010-03-15	Tranzyme Pharma Inc	Makrozyklische motilin rezeptorantagonisten
US20050152942A1 (en) *	2003-12-23	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US20050221429A1 (en) *	2004-01-16	2005-10-06	Cardinal Health Pts, Llc	Host cells containing multiple integrating vectors comprising an amplifiable marker
NZ550340A (en) *	2004-03-17	2010-08-27	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle using a retinoid
DE102004019413A1 (de) *	2004-04-19	2005-11-24	Phenos Gmbh	Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US20090111786A1 (en) *	2004-12-03	2009-04-30	Glass Christopher K	Compounds that Prevent Macrophage Apoptosis and Uses Thereof
WO2006068988A1 (en) *	2004-12-20	2006-06-29	Eli Lilly And Company	Combination therapy for vascular complications associated with hyperglycemia
US8034823B2 (en) *	2005-02-22	2011-10-11	Savvipharm Inc	Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
WO2006108270A1 (en) *	2005-04-11	2006-10-19	Pharmagap Inc.	Inhibitors of protein kinases and uses thereof
US8508369B2 (en)	2006-09-01	2013-08-13	Intermec Ip Corp.	RFID tag system with block coding, such as space-time block coding
AR069799A1 (es) *	2007-12-21	2010-02-17	Novartis Ag	Composicion farmaceutica
EP2181999A1 (en)	2008-11-03	2010-05-05	Zentiva, A.S.	Method of manufacturing ruboxistarin
US9265764B2 (en) *	2009-02-27	2016-02-23	Massachusetts Institute Of Technology	Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
BR112012024585A2 (pt)	2010-03-30	2016-05-31	Novartis Ag	inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
PL2925366T3 (pl)	2012-11-29	2018-08-31	Novartis Ag	Kombinacje farmaceutyczne
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en)	2016-12-19	2018-07-05	Chromaderm, Inc.	Methods of treating hyperpigmentation disorders
EP3600440A1 (en)	2017-03-20	2020-02-05	Sienna Biopharmaceuticals, Inc.	Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Polymer conjugates targeting c-src with reduced exposure
CN111065392B (zh)	2017-07-28	2024-10-25	应用治疗公司	用于治疗半乳糖血症的组合物和方法
KR20230005944A (ko)	2020-05-01	2023-01-10	어플라이드 테라퓨틱스 인크.	소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
KR20230128175A (ko) *	2022-02-25	2023-09-04	주식회사 온코크로스	루복시스타우린을 포함하는 항암용 조성물
CN119497614A (zh)	2022-05-20	2025-02-21	德慕拜昂生物科技公司	使用pk抑制剂来预防、治疗和改善皮肤疾病、病况和病症的组合物和制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK278989B6 (sk) *	1988-02-10	1998-05-06	F. Hoffmann-La Roche Ag	Substituované pyroly, ich použitie na výrobu lieči
US5292747A (en) *	1990-08-07	1994-03-08	Hoffman-La Roche Inc.	Substituted pyrroles
WO1994007895A1 (en) *	1992-09-25	1994-04-14	Schering Corporation	Diindolo compounds and pharmaceutical compositions containing them
BR9404831A (pt) *	1993-12-07	1995-08-08	Lilly Co Eli	Composto,formulação farmacêutica e processo de preparação de um composto
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors

1996
- 1996-11-18 TW TW085114103A patent/TW403754B/zh not_active IP Right Cessation
- 1996-11-18 AT AT96308318T patent/ATE172199T1/de active
- 1996-11-18 YU YU60996A patent/YU49315B/sh unknown
- 1996-11-18 DK DK96308318T patent/DK0776895T3/da active
- 1996-11-18 RO RO98-00955A patent/RO120074B1/ro unknown
- 1996-11-18 CA CA002237221A patent/CA2237221C/en not_active Expired - Fee Related
- 1996-11-18 PL PL96326754A patent/PL184715B1/pl not_active IP Right Cessation
- 1996-11-18 US US08/749,607 patent/US5710145A/en not_active Expired - Lifetime
- 1996-11-18 DE DE69600784T patent/DE69600784T2/de not_active Expired - Lifetime
- 1996-11-18 PE PE1996000829A patent/PE22798A1/es not_active Application Discontinuation
- 1996-11-18 EP EP96308318A patent/EP0776895B1/en not_active Expired - Lifetime
- 1996-11-18 BR BR9611724A patent/BR9611724A/pt not_active Application Discontinuation
- 1996-11-18 HU HU9903377A patent/HU226821B1/hu not_active IP Right Cessation
- 1996-11-18 NZ NZ323571A patent/NZ323571A/xx not_active IP Right Cessation
- 1996-11-18 IL IL12441796A patent/IL124417A/en not_active IP Right Cessation
- 1996-11-18 EA EA199800374A patent/EA000967B1/ru not_active IP Right Cessation
- 1996-11-18 ES ES96308318T patent/ES2122764T3/es not_active Expired - Lifetime
- 1996-11-18 JP JP51983697A patent/JP3348859B2/ja not_active Expired - Fee Related
- 1996-11-18 SI SI9630038T patent/SI0776895T1/xx unknown
- 1996-11-18 CN CN96198420A patent/CN1093759C/zh not_active Expired - Lifetime
- 1996-11-18 TR TR1998/00759T patent/TR199800759T2/xx unknown
- 1996-11-18 CZ CZ0150298A patent/CZ297524B6/cs not_active IP Right Cessation
- 1996-11-18 WO PCT/US1996/018512 patent/WO1997018809A1/en active IP Right Grant
- 1996-11-18 ZA ZA9609646A patent/ZA969646B/xx unknown
- 1996-11-18 AU AU10548/97A patent/AU711125B2/en not_active Ceased
- 1996-11-18 KR KR1019980703622A patent/KR100304210B1/ko not_active Expired - Fee Related
- 1996-11-18 UA UA98052515A patent/UA61897C2/uk unknown
- 1996-11-19 CO CO96060835A patent/CO4750823A1/es unknown
- 1996-11-19 EG EG102296A patent/EG23871A/xx active
- 1996-11-19 MY MYPI96004799A patent/MY118068A/en unknown
- 1996-11-20 AR ARP960105255A patent/AR004717A1/es not_active Application Discontinuation
- 1996-11-20 AR ARP960105254A patent/AR004336A1/es not_active Application Discontinuation
1997
- 1997-11-07 US US08/966,081 patent/US6015807A/en not_active Expired - Lifetime
1998
- 1998-05-13 MX MX9803792A patent/MX9803792A/es unknown
- 1998-05-13 NO NO19982182A patent/NO310196B1/no not_active IP Right Cessation
- 1998-11-19 CY CY9800046A patent/CY2103B1/xx unknown
1999
- 1999-12-07 US US09/455,697 patent/US6117861A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5710145A (en)	1998-01-20
PL184715B1 (pl)	2002-12-31
AU1054897A (en)	1997-06-11
MX9803792A (es)	1998-09-30
YU49315B (sh)	2005-06-10
EP0776895A1 (en)	1997-06-04
AU711125B2 (en)	1999-10-07
AR004717A1 (es)	1999-03-10
EA000967B1 (ru)	2000-08-28
WO1997018809A1 (en)	1997-05-29
EA199800374A1 (ru)	1998-10-29
AR004336A1 (es)	1998-11-04
ATE172199T1 (de)	1998-10-15
ZA969646B (en)	1998-05-18
IL124417A (en)	2002-11-10
CN1202825A (zh)	1998-12-23
KR19990067596A (ko)	1999-08-25
CZ297524B6 (cs)	2007-01-03
HU226821B1 (en)	2009-11-30
US6015807A (en)	2000-01-18
DE69600784D1 (de)	1998-11-19
UA61897C2 (en)	2003-12-15
PE22798A1 (es)	1998-05-11
CA2237221C (en)	2003-03-25
RO120074B1 (ro)	2005-08-30
US6117861A (en)	2000-09-12
HUP9903377A2 (hu)	2000-02-28
JPH11500149A (ja)	1999-01-06
TR199800759T2 (xx)	2001-01-22
ES2122764T3 (es)	1998-12-16
HUP9903377A3 (en)	2000-04-28
MY118068A (en)	2004-08-30
JP3348859B2 (ja)	2002-11-20
CN1093759C (zh)	2002-11-06
CZ150298A3 (cs)	1998-12-16
SI0776895T1 (en)	1999-04-30
NZ323571A (en)	1998-12-23
CY2103B1 (en)	2002-04-05
CA2237221A1 (en)	1997-05-29
EG23871A (en)	2007-11-27
NO310196B1 (no)	2001-06-05
YU60996A (sh)	1999-03-04
IL124417A0 (en)	1998-12-06
CO4750823A1 (es)	1999-03-31
NO982182L (no)	1998-05-13
NO982182D0 (no)	1998-05-13
BR9611724A (pt)	1999-06-01
DE69600784T2 (de)	1999-04-08
EP0776895B1 (en)	1998-10-14
KR100304210B1 (ko)	2001-11-05
PL326754A1 (en)	1998-10-26
TW403754B (en)	2000-09-01

Publication	Publication Date	Title
DK0776895T3 (da)	1999-06-23	Proteinkinase C inhibitor
NO974453L (no)	1997-11-19	Proteinkinase C-hemmere
DE69435267D1 (de)	2010-03-18	Proteinkinase C Inhibitoren
FI945706A7 (fi)	1995-06-08	Proteiinikinaasi C-inhibiittoreita
DE69627179D1 (de)	2003-05-08	Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
NO20002121D0 (no)	2000-04-26	Benzotiazol-protein-tyrosin-kinaseinhibitorer
NO992336D0 (no)	1999-05-14	Raf-kinase-inhibitorer
FI973492L (fi)	1997-08-26	NO-syntaasin estäjät
DE69323185D1 (de)	1999-03-04	Proteinkinase c-inhibitor
PT858464E (pt)	2003-08-29	Inibidores de trombina
DE69622983D1 (de)	2002-09-19	Chip-spule
DE69618742D1 (de)	2002-03-14	Schaltungsanordnung
PT863916E (pt)	2002-07-31	Tripeptidos de polifluoroalquil triptofano inibidores de trombina
DE69734817D1 (de)	2006-01-12	Neuartige amp-aktivierte proteinkinase
BR9610514A (pt)	1999-03-30	Inibidores cicloantihelmínticos
DE69619622D1 (de)	2002-04-11	Schaltungsanordnung
FI1943U1 (fi)	1995-06-09	Bomsystem till skogmaskin
KR960033453U (ko)	1996-11-19	건강음료 보약탕기
ITMI930345A0 (it)	1993-02-24	N-acil-peptidi inibitori delle protein-chinasi
KR970703937A (ko)	1997-08-09	금속단백질 분해효소 억제제(Metallproteinase inhibitors)
FI950022A0 (fi)	1995-01-02	Eosinofiiliset kemotaksiainhibiittorit
KR970048502U (ko)	1997-07-31	칩
ES1032844Y (es)	1996-12-01	Estanteria flotante
UA25624A (uk)	1998-12-25	Магhітооптичhа зчитувальhа головка
FI2002U1 (fi)	1995-07-07	Haollare till spoestaell